Motexafin gadolinium: A novel radiosensitizer for brain tumors

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 13, 2009, Pages 2171-2180

  Francis, Dave ^a   Richards, Gregory M ^a   Forouzannia, Afshin ^b   Mehta, Minesh P ^a   Khuntia, Deepak ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Center for Cancer Prevention and Treatment   (United States)

Author keywords

Brain metastasis; Glioblastoma; Motexafin gadolinium; Radiation sensitizer

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATININE; EFAPROXIRAL; GADOLINIUM TEXAPHYRIN; MISONIDAZOLE; TIRAPAZAMINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; BLISTER; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BRAIN TUMOR; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FECES; GLIOBLASTOMA; HUMAN; HYPERTENSION; INJECTION SITE REACTION; LIVER TOXICITY; LOADING DRUG DOSE; MUCOSA; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PAIN; PARESTHESIA; PERIPHERAL EDEMA; PRURITUS; RADIATION RESPONSE; RASH; REVIEW; SCLERA; SIDE EFFECT; SKIN DISCOLORATION; SURVIVAL RATE; SYSTEMIC THERAPY; TACHYCARDIA; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINE; WHOLE BODY RADIATION;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; HUMANS; METALLOPORPHYRINS; RADIATION-SENSITIZING AGENTS;

EID: 68949159748     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903179325     Document Type: Review

References (46)

1. Khuntia D, Brown P, Li J, Mehta MP. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 2006;24(8):1295-1304 (Pubitemid 46622033)
2. CBTRUS. Central Brain Tumor Registry of the United States 2008 statistical report: primary brain tumors in the United States; 2008. Available from: http://www.cbtrus.org/ [Cited 15 August 2008]
3. Nguyen T, Deangelis LM. Treatment of brain metastases. J Support Oncol 2004;2(5):405-10; discussion 11-16
4. Tsao MN, Lloyd N, Wong R, et al. Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst Rev 2006;3:CD003869
5. Patchell RA, Cirrincione C, Thaler HT, et al. Single brain metastases: surgery plus radiation or radiation alone. Neurology 1986;36(4):447-453 (Pubitemid 16069996)
6. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004;363(9422):1665-1672
7. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998;280(17):1485-1489 (Pubitemid 28507400)
8. Iliakis G, Kurtzman S. Application of non-hypoxic cell sensitizers in radiobiology and radiotherapy: rationale and future prospects. Int J Radiat Oncol Biol Phys 1989;16(5):1235-1241
9. Forouzannia A, Richards GM, Khuntia D, Mehta MP. Motexafin gadolinium: a novel radiosensitizer for brain tumors. Expert Rev Anticancer Ther 2007;7(6):785-794 (Pubitemid 47007985)
10. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 2007;25(26):4066-4074
11. Churchill-Davidson I. Hyperbaric oxygen and radiotherapy: general principles and problems. Nunt Radiol 1968;34(1):5-13
12. Suh JH, Stea B, Nabid A, et al. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol 2006;24(1):106-114 (Pubitemid 46630501)
13. Scott C, Suh J, Stea B, et al. Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases. Am J Clin Oncol 2007;30(6):580-587 (Pubitemid 350307182)
14. McGinn CJ, Lawrence TS. Recent advances in the use of radiosensitizing nucleosides. Semin Radiat Oncol 2001;11(4):270-280 (Pubitemid 32959662)
15. Morgan MA, Parsels LA, Maybaum J, Lawrence TS. Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review. Clin Cancer Res 2008;14(21):6744-6750
16. Khuntia D, Tome WA, Mehta MP. Radiation techniques in neuro-oncology. Neurother 2009;6(3):487-499
17. Viani GA, Castilho MS, Salvajoli JV, et al. Whole brain radiotherapy for brain metastases from breast cancer: estimation of survival using two stratification systems. BMC Cancer 2007;7:53
18. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-996 (Pubitemid 40349501)
19. Richards GM, Khuntia D, Mehta MP. Therapeutic management of metastatic brain tumors. Crit Rev Oncol Hematol 2007;61(1):70-78 (Pubitemid 44880147)
20. Shaw E, Scott C, Suh J, et al. RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the radiation therapy oncology group recursive partitioning analysis brain metastases database. J Clin Oncol 2003;21(12):2364-2371 (Pubitemid 46621875)
21. Khuntia D, Mehta M. Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors. Expert Rev Anticancer Ther 2004;4(6):981-989 (Pubitemid 39646555)
22. Chang JE, Khuntia D, Robins HI, Mehta MP. Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme. Clin Adv Hematol Oncol 2007;5(11):894-902, 7-15 (Pubitemid 351699408)
23. Carde P, Timmerman R, Mehta MP, et al. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol 2001;19(7):2074-2083 (Pubitemid 32702553)
24. Sessler JL, Miller RA. Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem Pharmacol 2000;59(7):733-739
25. Magda D, Lecane P, Miller RA, et al. Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines. Cancer Res 2005;65(9):3837-3845 (Pubitemid 40616364)
26. Rodrigus P. Motexafin gadolinium: a possible new radiosensitiser. Expert Opin Investig Drugs 2003;12(7):1205-1210 (Pubitemid 36857208)
27. Magda D, Lepp C, Gerasimchuk N, et al. Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int J Radiat Oncol Biol Phys 2001;51(4):1025-1036 (Pubitemid 33026434)
28. Evans JP, Xu F, Sirisawad M, et al. Motexafin gadolinium-induced cell death correlates with HO1 expression and inhibition of p450 reductase-dependent activities. Mol Pharmacol 2007;71(1):193-200 (Pubitemid 46020989)
29. Tonissen KF, Di Trapani G. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol Nutr Food Res 2009;53(1):87-103
30. Hashemy SI, Ungerstedt JS, Zahedi Avval F, Holmgren A. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J Biol Chem 2006;281(16):10691-10697 (Pubitemid 43855490)
31. Zahedi Avval F, Berndt C, Pramanik A, Holmgren A. Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd). Biochem Biophys Res Commun 2009;379(3):775-779
32. Avaal FZ, Berndt C, Pramanik A, Holmgren A. Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd). Biochem Biophys Res Commun 2009;379(3):775-779
33. Chen J, Ramos J, Sirisawad M, et al. Motexafin gadolinium induces mitochondrially-mediated caspase-dependent apoptosis. Apoptosis 2005;10(5):1131-1142 (Pubitemid 41285588)
34. Evens AM. Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer. Curr Opin Oncol 2004;16(6):576-580
35. Wu GN, Ford JM, Alger JR. MRI measurement of the uptake and retention of motexafin gadolinium in glioblastoma multiforme and uninvolved normal human brain. J Neurooncol 2006;77(1):95-103
36. Mehta MP, Rodrigus P, Terhaard CH, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003;21(13):2529-2536 (Pubitemid 46606335)
37. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37(4):745-751 (Pubitemid 27181303)
38. Meyers CA, Smith JA, Bezjak A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 2004;22(1):157-165 (Pubitemid 41095128)
39. Mehta MP, Shapiro WR, Phan SC, et al. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys 2009;73(4):1069-1076
40. Ford JM. A phase I dose escalation trial of motexafin gadolinium as a radiation sensitizer in patients with newly diagnosed glioblastoma multiforme. American Society of Therapeutic Radiation Oncologoy, San Francisco; 2001. p. 205
41. Suh J, Chang E, Timmerman R, et al. Phase II trial of motexafin gadolinium (MGd, Xcytrin) and cranial radiation in newly diagnosed glioblastoma multiforme (GBM). Proc Am Soc Clin Oncol (abstract) 2002;21(13):2108
42. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352(10):997-1003 (Pubitemid 40349502)
43. Rosenthal DI, Nurenberg P, Becerra CR, et al. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res 1999;5(4):739-745 (Pubitemid 29180823)
44. Bradley KA, Pollack IF, Reid JM, et al. Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study. Neuro Oncol 2008;10(5):752-758
45. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322(8):494-500
46. Amato RJ, Jac J, Hernandez-McClain J. Motexafin gadolinium for the treatment of metastatic renal cell carcinoma: phase II study results. Clin Genitourin Cancer 2008;6(2):73-78